Epoprostenol sodium is primarily used in the treatment of pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. It helps to dilate these arteries, reducing the strain on the heart and improving blood flow. This medication is particularly effective in patients with severe PAH, including those with idiopathic or hereditary forms of the disease, as well as PAH associated with connective tissue disorders.

Administered intravenously, epoprostenol sodium requires continuous infusion due to its short half-life. It is often used when other treatments have not been effective or are not suitable. By improving exercise capacity and delaying disease progression, it significantly enhances the quality of life for patients with this debilitating condition.

Additionally, epoprostenol sodium is sometimes utilized during certain surgical procedures, such as heart-lung bypass surgeries, to prevent blood clotting and maintain proper blood flow. It may also be used in hemodialysis for patients with kidney disease to prevent clotting in the dialysis circuit. Its vasodilatory properties make it a valuable tool in managing critical cardiovascular situations.

Overall, this medication plays a crucial role in managing PAH and supporting cardiovascular health in specific clinical scenarios.